| 非小细胞肺癌术后EGFR-TKIs治疗研究进展 |
| |
| 引用本文： | 卢子晴,于 洪.非小细胞肺癌术后EGFR-TKIs治疗研究进展[J].现代肿瘤医学,2020,0(19):3446-3449. |
| |
| 作者姓名： | 卢子晴 于 洪 |
| |
| 作者单位： | 中国医科大学肿瘤医院，辽宁省肿瘤医院放疗科，辽宁 沈阳 110042 |
| |
| 摘 要： | 肺癌是全球新发癌症发病率最高的癌症，也是中国最常见和致死率最高的癌症。其中85%为非小细胞肺癌（NSCLC），手术是早期患者的主要治疗手段，术后的标准辅助治疗为化疗。但部分患者从辅助化疗中获益十分有限，而且化疗的不良反应也严重影响了患者的生活质量和依从性。表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）的出现改变了晚期NSCLC患者的治疗模式，而术后辅助EGFR-TKIs治疗也已成为了国内外的研究热点。本文将对NSCLC术后EGFR-TKIs治疗的效果、安全性以及尚未解决的问题进行探讨。
|
| 关 键 词： | 非小细胞肺癌 表皮生长因子受体-酪氨酸激酶抑制剂 辅助治疗 |
Advances of postoperative EGFR-TKIs therapy for non-small cell lung cancer |
| |
| Lu Ziqing,Yu Hong.Advances of postoperative EGFR-TKIs therapy for non-small cell lung cancer[J].Journal of Modern Oncology,2020,0(19):3446-3449. |
| |
| Authors: | Lu Ziqing Yu Hong |
| |
| Affiliation: | Department of Radiotherapy，Cancer Hospital of China Medical University，Liaoning Cancer Hospital & Institute，Liaoning Shenyang 110042，China. |
| |
| Abstract: | Lung cancer has the highest incidence of new cancer cases in the world and is the most common and deadly cancer in China.Eighty-five percent of them are non-small cell lung cancer(NSCLC)，and surgery is the primary treatment for early stage patients.The standard postoperative adjuvant therapy is chemotherapy.However，some patients have limited benefits from it，and adverse reactions of chemotherapy also affect the quality of life and compliance of patients.The emergence of epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs) have changed the treatment mode of advanced patients，and postoperative adjuvant EGFR-TKIs treatment has become a hot topic at home and abroad.This article will discuss the efficacy，safety and unresolved issues of postoperative EGFR-TKIs therapy. |
| |
| Keywords: | NSCLC EGFR-TKIs adjuvant therapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
